Correct Answer: C. Steroids
Giant cell arteritis (GCA) is a large-vessel vasculitis that presents with the classic triad of headache, jaw claudication, and polymyalgia rheumatica (PMR). The presence of mononeuritis multiplex indicates cranial nerve involvement, raising the risk of vision-threatening complications (anterior ischemic optic neuropathy, central retinal artery occlusion). The discriminating fact is that GCA is a medical emergency requiring immediate high-dose corticosteroids to prevent irreversible blindness. Corticosteroids are the gold standard first-line treatment because they rapidly suppress the inflammatory cascade in the arterial wall, reduce ESR/CRP, and prevent ischemic complications. The typical starting dose is prednisolone 40–60 mg daily (or equivalent), tapered gradually over months based on clinical response and inflammatory markers. While immunosuppressants (abatacept, tocilizumab) and antiplatelet agents (aspirin) have adjunctive roles in steroid-sparing strategies or secondary prevention, neither can replace the urgent need for high-dose steroids at presentation. Indian guidelines and standard rheumatology practice (as per Harrison and Robbins) mandate immediate corticosteroid initiation in all suspected GCA cases, even before temporal artery biopsy confirmation, because the window for preventing blindness is narrow (days to weeks).
Why the other options are wrong
A. Abatacept — Abatacept (CTLA-4 Ig fusion protein) is a T-cell costimulation inhibitor used as a steroid-sparing agent in GCA, particularly in patients with steroid intolerance or dependence. However, it has no role as first-line monotherapy and cannot be used as an alternative to initial high-dose steroids. The NBE trap is offering a biologic agent to lure students who confuse GCA management with other vasculitides where biologics are primary agents. B. Aspirin — Low-dose aspirin (75–100 mg daily) is recommended as adjunctive antiplatelet therapy to reduce thrombotic complications in GCA patients already on steroids, but it is NOT first-line monotherapy. Aspirin alone cannot suppress the underlying vasculitic inflammation or prevent vision loss. This option exploits the misconception that antiplatelet agents are sufficient for vascular disease management. D. Tocilizumab — Tocilizumab (IL-6 receptor antagonist) is an emerging steroid-sparing agent approved by FDA for GCA and has shown efficacy in reducing relapse rates and steroid requirements. However, it is not first-line monotherapy and cannot replace urgent high-dose steroids at presentation due to the imminent risk of blindness. This is a modern trap—NBE includes newer biologics to test whether students prioritize immediate life-sight-saving therapy over newer agents.
High-Yield Facts
- GCA + PMR + headache + jaw claudication = medical emergency requiring immediate high-dose prednisolone 40–60 mg daily to prevent blindness within days.
- Anterior ischemic optic neuropathy (AION) is the most feared complication of untreated GCA; steroids must be started before biopsy if clinical suspicion is high.
- Mononeuritis multiplex in GCA indicates cranial nerve vasculitis (CN III, V, VII involvement); steroids are the only proven therapy to halt progression.
- Abatacept and tocilizumab are steroid-sparing agents used in relapsing GCA or steroid-dependent patients, never as monotherapy at presentation.
- ESR >50 mm/hr and CRP elevation support GCA diagnosis; temporal artery biopsy is gold standard, but steroids are started empirically if clinical suspicion is high.
Mnemonics
GCA RED FLAG Rapid onset headache, Elderly (>50 yr), D jaw claudication → First-line steroids, Low-dose aspirin adjunct, Avoid delay (blindness risk), Gold standard = prednisolone. PMR + GCA = STEROIDS STAT Polymyalgia + Moneuritis = Rapid steroid start. Giant cell arteritis = Corticosteroids (not biologics), Aspirin (adjunct only).
NBE Trap
NBE pairs GCA with newer biologics (abatacept, tocilizumab) to test whether students confuse steroid-sparing agents with first-line therapy. The trap is offering modern immunosuppressants to distract from the time-critical need for immediate high-dose steroids to prevent irreversible blindness.
Clinical Pearl
In Indian tertiary care, GCA is often diagnosed late because temporal artery biopsy facilities are limited and clinical suspicion is low in older patients presenting with "just headache." The key bedside pearl: any patient >50 years with new-onset headache + jaw claudication + elevated ESR should receive prednisolone 40–60 mg immediately, even before biopsy, because the risk of blindness within 1–2 weeks outweighs the risk of treating a false positive.
_Reference: Harrison Ch. 378 (Vasculitis); Robbins Ch. 10 (Vascular Pathology); KD Tripathi Ch. 28 (Corticosteroids in Vasculitis)_